Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Astellas Pharma will spend up to $108 million to acquire Quethera, a British gene therapy developer founded in 2015 based on the research of a University of Cambridge professor. Quethera is using recombinant adeno-associated viral vectors to introduce therapeutic genes into retinal cells for the treatment of glaucoma. Its lead candidate has yet to enter clinical trials.
This article has been sent to the following recipient: